medigraphic.com
ISSN 1405-8790 (Print)

2024, Number 1-4

<< Back Next >>

Rev Mex Med Fis Rehab 2024; 36 (1-4)

Electrophysiological classification and prognosis of walking ability in patients with Guillain-Barré syndrome at IMSS Yucatán

Pech ARC, Ortiz SPM, Gutiérrez PLL, Vargas ESL

Language: Spanish
References: 18
Page: 6-11
PDF size: 431.19 Kb.


ABSTRACT

Introduction: Guillain-Barré syndrome (GBS) is the most common cause of acute flaccid weakness worldwide, with an incidence of 1-2 per 100,000 person-years. The most common electrophysiological variant in Mexico is acute motor axonal neuropathy (AMAN), which doubles the recovery time for walking. Objective: to identify the electrophysiological variant and prognosis for walking in GBS patients from IMSS-Yucatan. Material and methods: retrospective observational study of eight patient records with a confirmed diagnosis of GBS and an electromyography report, from January 2020 to December 2022. Variables: age, sex, month/season, infectious history, MRC, mEGOS (Modified Erasmus GBS Outcome Score), electrophysiological variant, Hugues score, rehabilitation, and walking ability. Descriptive statistics were presented in tables and graphs using Excel/2021 software. Results: 75% (6) were men, with a mean age of 40.45 ± 23.49 years. 50% (5) had infectious antecedents, 87.5% (7) received rehabilitation, and 62.5% (5) recovered walking ability. The AMAN variant was found in 37.5% (3) and acute motor sensory axonal neuropathy (AMSAN) in 50% (4). 25% (2) had mEGOS scores ≥ 10, which translated into a high percentage of patients unable to walk without assistance, reaching up to 94% at one month, 70% at three months, and 51% at six months. Conclusions: the axonal variant predominated, with AMSAN being the most common. Higher mEGOS scores were associated with a greater percentage of patients experiencing long-term walking difficulties.


REFERENCES

  1. Levison LS, Thomsen RW, Christensen DH, Mellemkjaer T, Sindrup SH, Andersen H. Guillain-Barré syndrome in Denmark: validation of diagnostic codes and a population-based nationwide study of the incidence in a 30-year period. Clin Epidemiol. 2019; 11: 275-283.

  2. Galnares-Olalde JA, López-Hernández JC, García-Grimshaw M, Valdés-Ferrer SI, Briseño-Godínez ME, Sarachaga AJ et al. Guillain-Barré syndrome in Mexico: an updated review amid the coronavirus disease 2019 era. Rev Invest Clin. 2022; 74 (3): 121-130.

  3. Wen P, Wang L, Liu H, Gong L, Ji H, Wu H et al. Risk factors for the severity of Guillain-Barré syndrome and predictors of short-term prognosis of severe Guillain-Barré syndrome. Sci Rep. 2021; 11: 11578.

  4. Gee-Chiu AT, Ki-Chan RW, Yee-Yau ML, Lap-Yuen AC, Fai-Lam AK, Yin-Lau SW et al. Guillain-Barré syndrome in children-High occurrence of Miller Fisher syndrome in East Asian region. Brain Dev. 2022; 44 (7): 1-10.

  5. Tian J, Cao C, Li T, Zhang K, Li P, Liu Y et al. Electrophysiological subtypes and prognostic factors of Guillain-Barre syndrome in Northern China. Neurology. 2019; 10: 1-7.

  6. Khedr EM, Shehab MM, Mohamed MZ, Mohamed KO. Early electrophysiological study variants and their relationship with clinical presentation and outcomes of patients with Guillain-Barré syndrome. Nature. 2023; 13: 1-9.

  7. Kim SH, Samadov F, Mukhamedov A, Kong J, Ko A, Kim YM et al. Clinical characteristics and prognostic factors of children with Guillain-Barré syndrome. Ann Child Neurol. 2019; 27 (4): 113-119.

  8. Doets AY, Lingsma HF, Walgaard C, Islam B, Papri N, Davidson A et al. Predicting outcome in Guillain-Barré syndrome: international validation of the Modified Erasmus GBS Outcome score. Neurology. 2022; 98 (5): 518-532.

  9. Van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014; 10 (8): 469-482.

  10. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011; 36 (2): 123-133.

  11. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005; 366 (9497): 1653-1666.

  12. Kuwabara S, Yuki N. Axonal Guillain-Barré syndrome: concepts and controversies. Lancet Neurol. 2013; 12 (12): 1180-1188.

  13. Jacobs BC, Rothbarth PH, van der Meché FG, Herbrink P, Schmitz PI, de Klerk MA et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 1998; 51 (4): 1110-1115.

  14. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016; 388 (10045): 717-727.

  15. McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. Neuroepidemiology. 2009; 32 (2): 150-163.

  16. Kuwabara S. Guillain-Barré syndrome: epidemiology, pathophysiology, and management. Clin Exp Neuroimmunol. 2016; 7 (1): 11-15.

  17. Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med. 2012; 366 (24): 2294-2304.

  18. Khan F, Amatya B. Rehabilitation in Guillain-Barré syndrome. Aust Fam Physician. 2012; 41 (4): 244-248.




2020     |     www.medigraphic.com